20/20 GeneSystems, Inc. offering is now closed and is no longer accepting investments.
INVEST IN 20/20 GENESYSTEMS, INC. TODAY!
Lab-Based Diagnostic Testing Powered by AI and Real-World Data
$232,186.66 Raised
Reasons to Invest
- One of the first in a fast growing market: 20/20 GeneSystems is one of the first organizations in the white-hot market for multi-cancer early detection (MCED) screening blood tests and is collecting test outcome data from around the world to help us refine and improve our algorithms and remain a market leader. Since the start of 2022 advancing MCEDs has become a priority for members of Congress and the U.S. National Cancer Institute.
- Experienced Team: Our CEO previously established strategic partnerships with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics and Smiths Detection. Our Board members have built and sold several successful diagnostics and medtech companies.
- Investor backing: Our shareholders include China’s Ping An Ventures, likely the world’s largest Healthcare AI company (300 million users of its mobile diagnostic app) & thousands of investors, as well as the Keiretsu Forum, family offices, and over 8,000 crowd investors.
overview
Lab Testing Made Smarter
20/20 GeneSystems, Inc. is one of the fastest growing privately-owned companies in the nation. Steadfastly committed since its inception to developing a leading position in the cancer screening market, 20/20 GeneSystems successfully leveraged its clinical laboratory operational skills and technical expertise to expand its viral testing services to meet the needs of the community during the COVID-19 pandemic.
Learn More: Yahoo! Finance
We believe OneTest is one of the first tests of its kind to combine the results of six cancer biomarker tests (from a single blood draw) and personal health data with an artificial intelligence algorithm to calculate a probability score for many different types of cancers.
The Problem
We Usually Don't Catch Cancer Early Enough
Cancer is the 2nd leading cause of death in most of the industrialized world with survival rates closely tied to stage at time of diagnosis. For example, the 5-year survival rate for lung cancer falls 90% when it passes from Stage 1 to Stage 4.
The Solution
20/20 GeneSystems' OneTest: A Machine Learning Enhanced Blood Test to Help Detect Multiple Cancers Early
20/20 GeneSystems develops and commercializes clinical laboratory tests that are improved with machine learning and real-world data. Through our high-complexity CLIA lab we offer what is believed to be one of the first multi-cancer screening blood tests in the U.S. costing under $200. In response to the global pandemic, we expanded our CLIA laboratory test menu to include PCR testing. This expansion allowed us to scale our COVID testing operation and as a result our 2021 revenues to $9,622,332 increasing revenues from 2020 by $7,291,804 and net income for 2021 is $2,071,777.
Learn More: Yahoo! Finance
OneTest™ aids in the early detection of multiple cancers from one blood sample. See www.OneTest.AI. Individuals can easily order the test on our website and then visit a nearby retail clinic for blood sample collection. The blood samples are forwarded to our CLIA lab where they are analyzed for the levels of a panel of tumor antigens. These levels are then compared with the consumers' prior test results as well as those of over 200,000 individuals with known cancer outcomes that have had these biomarkers tested previously. A machine learning algorithm then predicts the likelihood of having cancer. Doctors’ familiar with the workings of this test are available to consult via telemedicine.
*This video includes computer generated images to simulate the one test process.
Key features of the current product are as follows:
A cloud accessible tool to improve the accuracy of tumor marker blood tests (CEA, AFP, CA-19.9, etc.)
Useful in early detection of multiple types of cancer (lung, liver, pancreas, etc.)
Incorporates clinical factors (age, gender, smoking history, etc.)
Stores & displays each individual’s biomarker trends from successive tests
Uses machine learning / AI
To the best of our knowledge, 20/20 GeneSystems is one of the first companies to commercialize multi-cancer screening blood tests powered by AI and machine learning algorithms built with real-world outcome data from tens of thousands of previously tested individuals. Screening tests and algorithms must be validated in a “pre-diagnostic” population (i.e. individuals tested before being diagnosed with cancer) to be proven reliable. Our approach of “harvesting” real-world data permits rapid validation from this population with limited costs.
We sell OneTest (www.OneTest.AI) to both individuals and occupational groups (e.g. Fire Departments) with proven high cancer risk.
our traction
Growing Year-Over-Year
This represents an increase of more than 300% increase over 2020 revenues and more than 3,000% increase over 2019 revenues ($288,300). With our ability to enhance our operations with COVID testing, we ranked no. on the Inc. 5000 list of America’s fastest growing companies in 2021 and expect to rank in the top 200 on this year’s list.
Key goals and priorities to help yield sustained commercial traction and revenue growth in the 24 month period following the pandemic emergency include the following:
- Significantly Grow OneTest for Cancer in the USA. Expanding the number of retail clinics that draw blood for OneTest from 125 to 500 would permit faster scale of this product .
- Develop OneTest for Heart Health. We have several partnerships underway with both commercial entities and researchers about a panel of blood based cardiac markers that can be combined with data from wearables such as blood pressure and EKG and use machine learning algorithms that can help predict the likelihood of cardiac arrest and stroke.
- New Tests for Wellness, Prevention, and Early Detection. We are signing up market ready diagnostic companies into the Clinical Laboratory Innovation AxceleratorTM; One partner from Australia has begun to set their operation on site and others are in discussion. These partnerships will provide for co-marketing arrangements along with royalty and service fees in exchange for operating in the accelerator.
The Market
Multi-Cancer Screening Blood Tests are for Everyone
Recent studies by leading cancer geneticists at Johns Hopkins suggest that far more cancers are caused by aging than from family history, the environment, or lifestyle. This suggests that all adults, beginning in middle age, should be screened regularly for a wide array of cancers. In fact, throughout East Asia most adults receive tumor antigens testing each year at “Health Check Centers.”
Thus, the market for multi-cancer screening blood tests includes all adults roughly between the ages of 45 and 75 (the optimum ages for cancer screening). According to our research, there are no widely used safe and affordable tests that help identify as many cancers as our OneTest at comparable price and accuracy levels.
While we see OneTest being a universal test in the long-term, in the near-term we are focusing on occupations with proven high incidents of lethal cancers. Studies by the U.S. National Institute of Occupational Safety & Health (NIOSH) demonstrate that firefighters are one such occupation. Thus, America’s more than one million career and volunteer firefighters are a key market for OneTest. See www.OneTestforCancer.com/firefighters.
why invest
Invest in Saving Lives
20/20 GeneSystems is pioneering a brand new approach to improve the accuracy and usefulness of conventional clinical lab testing. Rather than simply reporting the biomarker levels, in the way they have for decades, we leverage vast amounts of real-world data together with machine learning to compare the individual’s test results to those of tens of thousands of others with known health outcomes. This proprietary technique is already being used to improve early cancer detection and will soon be deployed to help flag risks of heart attacks and other serious diseases.
CLIAx: bringing cutting edge lab tests to market
Join us!
Learn More: Yahoo! Finance
ABOUT
HEADQUARTERS
15810 Gaither Road, Suite 235
Gaithersburg, MD 20877
VALUATION
$59.91M
PREVIOUSLY CROWDFUNDED
$10M
20/20 GeneSystems develops and commercializes clinical laboratory tests that are improved with machine learning and real-world data. Through our high-complexity CLIA lab, we offer what is believed to be the first multi-cancer screening blood test in the U.S. costing under $200. In response to the global pandemic, we expanded our CLIA laboratory test menu to include PCR testing. Due to our ability to scale our COVID testing operation, 2021 revenues exceeded $9 million with over $1 million in net profits for the year. This represents a more than 300% increase over 2020 revenues. As a result, we ranked no. 131 on the Inc. 5000 list of America’s fastest-growing companies in 2022. To grow our portfolio of tests, the Company has built a Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first accelerator facility for diagnostics start-ups. Our CLIAx is expected to help fuel our product and revenue growth for the next five years and already has two companies signed up to join.
TEAM
Jonathan Cohen
Chief Executive Officer, President and Director
Jiming Zhou
Chief Operating Officer
Michael Lebowitz
Chief Scientific Officer
Amy Colton
Senior Sales
Ron Baker
Sales Director
Alexis Levy
Senior Sales Representative
Anne Shiflett
Director of Finance
John Compton
Chairman of the Board of Directors
Richard M. Cohen
Director
John W. Rollins
Director
Michael A. Ross
Director
Ming Li
Director
Investment cases include Cloudr Group (9955.HK), General Healthy (605186.SH), HuaTong (605196.SH), BEKE.US.
Before joining Ping An Ventures, Li Ming was the executive director in Ping An Bright Fortune Capital, and investment director in Fosun Capital covering medical service and TMT investment business.
Li Ming holds an MBA degree from Cheung Kong Graduate School of Business.
Li Ming was the Executive Director of Ping An Ventures in the past 3 years.
TERMS
20/20 GeneSystems, Inc.
Overview
INTEREST RATE
6.0%
MATURITY DATE
Feb 28, 2025
VALUATION CAP
$58.4M
AMOUNT RAISED
$232,186.66
Breakdown
MIN INVESTMENT
$500.00
DISCOUNT RATE
10.0%
CONVERSION TRIGGER
$100,000.00
OFFERING TYPE
Convertible Notes
TYPE OF EQUITY
Non-Voting Common Stock
Company | : | 20/20 GeneSystems, Inc. |
Corporate Address | : | 15810 Gaither Road, Suite 235, Gaithersburg, MD 20877 |
Offering Minimum | : | $9,995.40 |
Offering Maximum | : | $4,999,995.00 |
Minimum Investment Amount(per investor) | : | $500.00 |
Terms
Offering Type | : | Convertible Promissory Notes |
Type of Equity Converted Into | : | Common Stock |
Conversion Trigger | : | $100,000.00 |
Maturity Date | : | February 28, 2025 |
Valuation Cap | : | $58,400,000.00 |
Discount Rate | : | 10.0% |
Annual Interest Rate | : | 6.0% |
What is a Convertible Note?
A convertible note offers you the right to receive Common Stock in 20/20 GeneSystems, Inc.. The amount of Common Stock you will receive in the future will be determined at the next equity round in which the Company raises at least $100,000.00 in a qualified equity financing. The highest conversion price per security is set based on a $58,400,000.00 Valuation Cap or if less, then you will receive a 10.0% discount on the price the new investors are paying. You also receive 6.0% interest per year added to your investment. When the maturity date is reached, if the note has not converted then you are entitled to receive Common Stock equal to your investment and interest back at a price per security determined by dividing the Valuation Cap by the aggregate number of outstanding equity securities of the Company as of immediately prior (on a fully diluted basis).
Investment Incentives and Bonuses*
Time-Based:
Invest within the first 2 weeks and receive a 25% increase in the annual interest rate on Convertible Promissory Notes in this Offering, where by the interest rate will increase from 6% to 7.5%.
Amount-Based:
Tier 1 | $500+
Receive 1/3 off all 20/20 lab tests for 12 months. (Only if available in your country)
Tier 2 | $1,000+
Receive 1/2 off all 20/20 lab tests for 12 months. (Only if available in your country)
Tier 3 | $2,500+
Receive 1/2 off all 20/20 lab tests for 18 months. (Only if available in your country)
Tier 4 | $5,000+
Receive 1/2 off all 20/20 lab tests for 24 months. (Only if available in your country)
Tier 5 | $10,000+
Receive 1/2 off all 20/20 lab tests for life. (Only if available in your country)
*All perks occur when the offering is completed.
Audience-Based Perk
Loyalty Bonus | 50% bonus on interest
Previous 20/20 GeneSystems investors are eligible for an additional bonus on interest.
The 10% StartEngine Owners' Bonus
20/20 GeneSystems, Inc. will offer a 10% additional bonus for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
Eligible StartEngine shareholders will receive a 10% increase in the annual interest rate on Convertible Promissory Notes in this Offering. This means your annual interest rate will be 6.6% instead of 6%.
This 10% Bonus is only valid during the investors' eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the Company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the Offering become available if prior investments are canceled or fail.
Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.
Irregular Use of Proceeds
We will not incur any irregular use of proceeds.
ALL UPDATES
12.14.22
Only 2 days left to invest in 20/20 Gene Systems!
Join us as we help bend the curve of cancer mortality in the U.S. through earlier detection. Our campaign ends on 12/15/2022 at 11:59:59PM PST.
12.12.22
20/20 Gene Systems, Inc. Start Engine Campaign ends in less than 3 days!
At this time, 20/20 Gene Systems has decided to end its current financial raise. The Campaign ends at 11:59:59PM PST on 12/15/2022. We thank all those that invested since the beginning of this campaign, 8/15/2022 and encourage those that have not yet invested, to do so within the next week. If you want to stay up date on our progress, visit our website at www.2020gene.com. Keep an eye out for our Quarterly Newsletter and if you have not already done so, view our recent 20/20 Informational Webinar at the Webinar Link.
11.29.22
Making Cancer Testing More Convenient
Last week we participated in HLTH 2022, a very exciting healthcare conference in Las Vegas attended by over 10,000 companies, entrepreneurs, investors, and medical providers. While there we met with leaders from several large retailers and pharmacy chains as well as companies that have developed new devices to collect capillary blood to avoid the need for traditional, often painful venous blood draws.
20/20’s vision is that for cancer screening to be impactful it must be both affordable, convenient and easily accessible. One tool to advance that goal is to make our OneTest for Cancer and our other products available at local pharmacies using fingerstick collected blood (typically pharmacies to not employ phlebotomists that draw blood from the arm). Next month we are initiating a study comparing the equivalency of capillary collected blood with venous blood for the tumor antigens that are measured in our test. To the best of our knowledge these equivalencies have not yet been established by others.
We expect to have more to report on these exciting efforts to make OneTest available at national pharmacy chains during the first Quarter of the new year.
11.23.22
20/20 Informational Webinar available for your Review
If you missed the live Webinar on November 17, 2022 at 12PM EST, the link to review at your convenience is noted below:
https://us02web.zoom.us/rec/share/ecRcpD444ESaxEyZ1Y8gxzRZS2kIbm2sBWH5u_WU2juH-n8sKKlMprUWjnzikx2d.Yan18RIBqx5mEXGn?startTime=1668704369000
Passcode: Yr46gb#D
11.14.22
Notice of Material Change in Offering
[The following is an automated notice from the StartEngine team].
Hello! Recently, a change was made to the 20/20 GeneSystems, Inc. offering. Here's an excerpt describing the specifics of the change:
Issuer is extending campaign end date
When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.
11.10.22
One Week Until the 20/20 Investor Webinar - REGISTER NOW
Join Jonathan Cohen, CEO for an Investor Webinar on Nov 17, 2022 12:00 PM Eastern Time. This will give you a chance to ask questions and learn more about the Company.
We look forward to you joining us for this Webinar.
Register in advance for this meeting:
https://us02web.zoom.us/meeting/register/tZMtdeGurzosHtb0J40d0AqrWQazd2M9tJr3
After registering, you will receive a confirmation email containing information about joining the meeting.
11.07.22
Join Our Investor Webinar on November 17, 2022 12:00PM EST
Join Jonathan Cohen, CEO for an Investor Webinar on Nov 17, 2022 12:00 PM Eastern Time. This will give you a chance to ask questions and learn more about the Company.
We look forward to you joining us for this Webinar.
Register in advance for this meeting:
https://us02web.zoom.us/meeting/register/tZMtdeGurzosHtb0J40d0AqrWQazd2M9tJr3
After registering, you will receive a confirmation email containing information about joining the meeting.
11.01.22
California, Here We Come!
20/20's high complexity clinical laboratory, currently regulated under CLIA and the State of Maryland, just received accreditation from the College of American Pathologists. CAP Accreditation is a pre-requisite for a license from the California Department of Public Health to receive and process specimens from California residents, which was also received last month. We estimate that about 20% of consumers interested in our tests reside in that state.
10.19.22
Wall Street Journal covers the new and growing market of MCEDs
Last week the Wall Street Journal had a feature story on the momentum of multi-cancer early detection (MCED) blood tests. The story can be downloaded here. We believe that 20/20, along with Grail, are among the first entrants into a market that will grow to $50 billion in yearly sales according to the analyst cited in the article. Our approach of measuring tumor antigens—rather than DNA biomarkers—permits far less expensive tests ($189 vs. $949) without demonstrated loss of accuracy.
10.18.22
20/20 Runs Full Page Ad in Prevention Magazine
We’ve achieved another major milestone in our integrated campaign with Prevention magazine. During the week of October 10th, hundreds of thousands of subscribers of Prevention and newsstands began to receive the November issue of the magazine, which features our one-page, informative, advertisement for OneTest for Cancer. This piece of credible marketing collateral significantly extends the reach of visibility for OneTest for Cancer and increases the opportunity for the health-conscious consumer to engage with our brand. These touchpoints of the campaign could not come at a more opportune time as we’ve begun to see greater awareness and understanding for MCEDs and are enthusiastic about the continued momentum this will drive.
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
$500.00
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$500.00
Tier 1
Receive 1/3 off all 20/20 lab tests for 12 months. (Only if available in your country)
$1,000.00
Tier 2
Receive 1/2 off all 20/20 lab tests for 12 months. (Only if available in your country)
$2,500.00
Tier 3
Receive 1/2 off all 20/20 lab tests for 18 months. (Only if available in your country)
$5,000.00
Tier 4
Receive 1/2 off all 20/20 lab tests for 24 months. (Only if available in your country)
$10,000.00
Tier 5
Receive 1/2 off all 20/20 lab tests for life. (Only if available in your country)
JOIN THE DISCUSSION
0/2500
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
